Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer
2022
Abstract
Niraparib is a small molecule targeted therapy, an inhibitor of poly-ADP-ribose polymerase (PARP), which is involved in the repair of DNA breaks. However, its therapeutic effect is also due to other mechanisms of action and its clinical impact within the maintenance treatment is evident practically regardless of the state of homologous recombination, resp.
BRCA mutations, in patients with advanced high-grade ovarian cancer (meaning ovary, fallopian tube or primary peritoneal cancer) after achieving a response not only in the first line treatment.